mind & bodyScienceDaily
An anti-aging drug may help protect the brain before Alzheimer's symptoms begin
explained
Sirolimus, also known as rapamycin and sold under the brand name Rapamune among others, is a macrolide compound that is used to coat coronary stents, prevent organ transplant rejection, treat a rare lung disease called lymphangioleiomyomatosis, and treat perivascular epithelioid cell tumour (PEComa). It has immunosuppressant functions in humans and is especially useful in preventing the rejection of kidney transplants. It is a mammalian target of rapamycin (mTOR) kinase inhibitor that reduces the sensitivity of T cells and B cells to interleukin-2 (IL-2), inhibiting their activity.
This compound also has a use in cardiovascular drug-eluting stent technologies to inhibit restenosis.
From Wikipedia: Sirolimus (CC BY-SA 4.0) ↗Alzheimer's is often diagnosed only after significant damage has occurred, so early protective strategies are a major goal. If rapamycin proves beneficial in larger trials, it could offer a way to intervene before memory loss starts. Researchers still need longer studies to confirm safety and effectiveness.
Rapamycin was first isolated from soil bacteria collected on Easter Island, whose local name is Rapa Nui.
Illustrative photo · Vaccinationist, Public domain, via Wikimedia Commons
